A carregar...
Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
BACKGROUND: The recently published cardiovascular outcomes data for the first sodium–glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, have shown cardiovascular safety and additional benefits in patients with type 2 diabetes and established cardiovascular disease. Empagliflozin showed lower...
Na minha lista:
| Publicado no: | Int J Gen Med |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5245975/ https://ncbi.nlm.nih.gov/pubmed/28144158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJGM.S115566 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|